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Abstract—We have found that a well-characterized P2X7 receptor antagonist AZ11645373 blocked
production of pro-inflammatory chemokine IL-8 in endothelial cells treated with OxPAPC. The effect
was not due to toxicity of AZ11645373 as documented by cellular metabolic activity assay. The
mechanism of inhibition by AZ11645373 was apparently independent of the P2X7 receptor because
this receptor was not involved in induction of IL-8 under our experimental conditions. In support of this
notion, two P2X7 agonists ATP and BzATP did not upregulate IL-8. On the other hand, a chemically
different P2X7 receptor antagonist A740003 did not inhibit OxPAPC-induced production of IL-8. The
inhibitory action of AZ11645373 was observed at the level of IL-8 protein and messenger RNA
(mRNA) induction. Furthermore, AZ11645373 inhibited induction of mRNA encoding for COX-2
(PTGS2) suggesting that its anti-inflammatory potential is not limited to suppression of IL-8 production.
In addition to inhibiting stimulation by OxPAPC, AZ11645373 suppressed induction of IL-8 by TNFα
and LPS. To summarize, AZ11645373 inhibits in a P2X7-independent manner action of chemically
different inflammatory agonists such as OxPLs, LPS, and TNFα. Thus, AZ11645373 may be especially
effective for treatment of inflammatory disorders due to a beneficial combination of P2X7 receptor-
dependent effects (inhibition of inflammasome activation, antinociceptive effects) with P2X7-
independent general anti-inflammatory action described in this paper.
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INTRODUCTION
P2X7 receptor antagonists demonstrate antinociceptive
and anti-inflammatory action and some of them are now in
clinical trials for treatment of chronic inflammatory diseases
[1–3]. It is generally accepted that the anti-inflammatory
action of P2X7 receptor antagonists is mediated through
the inhibition of P2X7 receptor-dependent activation of the
NLRP-3 inflammasome [4–6]. Activation of P2X7 receptors
by extracellular adenosine triphosphate induces efflux of
potassium ions from cells resulting in activation of caspase-
1, which processes IL-1β and IL-18 precursor proteins to the
mature active cytokines [7]. In this work, we have tested a
known P2X7 receptor antagonist AZ11645373 for its ability
to inhibit induction of an inflammatory cytokine IL-8 in
human endothelial cells. Here, we show that AZ11645373
inhibits induction of IL-8 by oxidized phospholipids, LPS, or
TNFα and that this inhibitory effect is an off-target phenom-
enon independent of its action on P2X7 receptor.
MATERIALS AND METHODS
Preparation of OxPAPC
1-Palmi toyl -2-arachidonoyl-sn -g lycero-3-
phosphocholine(AvantiPolarLipids;Alabaster,AL,USA)was
oxidized by exposure to air for 24 h until approx. 20% of the
phospholipid remained intact. The oxidation progress was
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monitored by thin-layer chromatography and by mass spec-
trometry [8].
Cell Culture
Human umbilical vein endothelial cells (HUVECtert)
were cultured in NunclonTM Delta surface flasks (Bartelt;
Graz, Austria) in medium 199 (Gibco; Carlsbad, CA,
USA) supplemented with 20% fetal calf serum (FCS)
(Sigma-Aldrich; St. Louis, MO, USA), penicillin-
streptomycin-amphotericin B (Lonza; Basel, Switzerland),
and ECGS-heparin (PromoCell; Heidelberg, Germany) in
the 95% humidified atmosphere with 5% CO2 at 37 °C.
Stimulation of cells was performed in endothelial basal
medium-2 (EBM-2) (Lonza) supplemented with 2% FCS
(Sigma-Aldrich), and 20 mM HEPES (Lonza). The cells
were preincubated with an inhibitor solution for 20 min.
Then, an agonist solution was added to the cells. After 7 h
of the incubation at 37 °C, cell culture supernatants were
collected for ELISA. At the end of the experiment, viability
of the remaining cells was measured using a tetrazolium
salt (XTT) assay. Following inhibitors and agonists used
were purchased from Sigma-Aldrich: AZ11645373,
A740003, Ac-YVAD-cmk, LPS 005:B5, ATP, BzATP. Re-
combinant human TNFα was from PeproTech (Rocky
Hill, NJ, USA).
IL-8 ELISA
IL-8 in cell culture supernatants after the stimulation
of cells was detected by a CXCL8/IL-8 DuoSet ELISA Kit
(R&D Systems; Minneapolis, MN, USA) according to
manufacturer’s instruction. Briefly, MaxiSorp 96-well
plates (ThermoScientific; Waltham, MA, USA) were pre-
coated with the capture antibody (4 μg/ml in PBS), incu-
bated for 2 h at rt, and washed four times with 0.05%
Tween 20 (Sigma-Aldrich) in PBS (v/v) using a
HydroSpeedTM washer (Tecan Group Ltd; Männedorf,
Switzerland). Blocking was performed with 1% bovine
serum albumin (BSA) (Carl Roth; Karlsruhe, Germany)
in PBS (w/v) for 1 h at rt. After washing, supernatants or
IL-8 standard were added to wells and incubated for 2 h at
rt followed by another washing step. The detection anti-
body was diluted to 20 ng/ml with 0.1% BSA/0.05%
Tween 20 in PBS (w/v/v), added to the plate and incubated
for 1 h at rt. After another washing step, streptavidin-HRP
was added and incubated for 30 min at rt, followed by a
final washing step. The substrate OPD (ThermoScientific)
was added and incubated at 37 °C in the dark until the color
development. Absorbance was periodically measured
using a multimode plate reader EnSightTM (Perkin Elmer;
Waltham, MA, USA) at 450 nm to avoid values above 0.4.
After addition of 1 M sulfuric acid (ThermoScientific) to
stop the reaction, final absorbance was measured at
492 nm.
Cell Viability Assay—XTT
At the end of cell stimulation, metabolic activity of
cells was determined. Triton X-100 (0.2% final concentra-
tion) was added to cells for 15 min for the negative control.
Medium was exchanged to medium 199 with 0.2 mg/ml
2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazoli-
um-5-carboxanilide (Molecular Probes; Eugene, OR,
USA) and 5 nM phenazine methosulfate (Acros-Organic;
Geel, Belgium). After 4 h of incubation at 37 °C, absor-
bance at 450 nm was measured.
RNA Isolation and RT-qPCR
Cells were preincubated with a solution of
AZ11645373 in EBM-2/2% FCS/20 mM HEPES for
20 min followed by addition of OxPAPC (30 to 40 μg/
ml) in the same medium. After incubation for 6 h at 37 °C,
the medium was removed and RNAzol®RT (Molecular
Research Center Inc.; Cincinnati, OH, USA) was added
and total RNAwas isolated. Concentrations of RNAwere
determined using a DS-11+Spectophotometer (DeNovix;
Wilmington, DE, USA).
Nine hundred nanograms of RNA were reverse-
transcribed using murine leukemia virus reverse transcrip-
tase (MuLV) and oligo(dT)16 primers (both from Applied
Biosystems; Foster City, CA, USA). Complementary DNA
(cDNA) was analyzed using a SYBRGreen master mix
(PCR Biosystems Ltd; London, UK) on a StepOnePlus
instrument (Applied Biosystems) using a comparative ΔCt
method and the amplification program as follows: 30 s at
90 °C, 40× (3 s at 95 °C, 30 s at 60 °C); melting point
analysis in 0.1 °C steps. Sequences of primers used are β2-
microglobulin (B2M, β2M) (fwd: 5′-ATT CAC CCC CAC
TGA GAC TG-3′, rev: 5′-TGC TAT TTC TTT CTG CGT
GC-3′), IL-8 (fwd: 5′-CTC TTG GCA GCC TTC CTG
ATT-3′, rev: 5′-TAT GCA CTG ACA TCT AAG TTC
TTT AGC A-3′), PTGS2 (fwd: 5′-CCG CAA ACG CTT
TAT GCT GAA-3′, rev: 5′-TGG CCG AGG CTT TTC
TAC CA-3′). Quantification of target gene expression was
performed using a mathematical model by Pfaffl [9]. The
expression of messenger RNA (mRNA) of target genes was
normalized to the expression of β2-microglobulin mRNA.
In all experiments, β2-microglobulin-normalized level of
expression in control cells was taken as 1.
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Statistical Analyses
The results are representative of two to four indepen-
dent experiments. Mean values and standard deviations for
at least three parallels are presented. A one-way ANOVA
analysis with the Tukey post hoc correction was used for
calculation of statistical significance. Values with p ≤ 0.05
were considered as statistically significant.
RESULTS
Oxidized phospholipids such as oxidized 1-
palmitoyl-2-arachidonoy-sn-3-glycerophosphocholine
(OxPAPC) accumulate within the atherosclerotic lesion
and induce pro-inflammatory activation of endothelial cells
[10] including upregulation of chemokine IL-8 [11].
Concentration-dependent upregulation of IL-8 by
OxPAPC in HUVECtert cells is illustrated in Fig. 1a. We
found that the IL-8 release was blocked by an antagonist of
P2X7 receptor, AZ11645373 (Fig. 1b). The inhibitory
effect was not due to the toxicity of AZ11645373 as
documented by the metabolic activity (XTT) assay per-
formed at the end of the experiment (Fig. 1c). In addition to
the downregulation of IL-8 protein, also IL-8mRNA levels
were decreased (Fig. 2a). OxPAPC-induced upregulation
of another pro-inflammatory gene, COX-2 (PTGS2) was
also suppressed by AZ11645373 (Fig. 2b). The data allow
hypothesizing that AZ11645373 inhibited general pro-
inflammatory mechanisms that are upstream of IL-8 and
COX-2 (PTGS2) gene transcription.
AZ11645373 was described as a high-affinity antag-
onist of human P2X7 receptor [12]. In order to test if
indeed the inhibitory action of AZ11645373 was mediated
by its antagonism of the P2X7 receptor, we used two
approaches. First, we checked if the P2X7 receptor is
involved in upregulation of IL-8. The data of Fig. 3a, b
demonstrate that two P2X7 receptor agonists, namely ATP
and its higher-affinity-derivative BzATP, did not signifi-
cantly upregulate IL-8. The data suggest that under the
conditions of our experiments the induction of IL-8 was
independent of the P2X7 receptor. This hypothesis is in
general agreement with the known involvement of P2X7
receptors in activation of NLRP3 inflammasome that pro-
duces two major cytokines—IL-1β and IL-18 through
caspase-1-dependent mechanism [7] that is different from
the mechanisms inducing IL-8 expression. In agreement
with these arguments, a caspase-1 inhibitor Ac-YVAD-
cmk did not inhibit induction of IL-8 byOxPAPC (Fig. 3c).

















































































































































Fig. 1. AZ11645373 inhibits OxPAPC-induced IL-8 release in endothelial
cells. a OxPAPC induces IL-8 release. HUVECtert cells were stimulated by
OxPAPC at the indicated concentrations for 6 h in EBM-2/2% FCS/20 mM
HEPES in a 96-well plate. The concentrations of IL-8 released into the culture
mediumwere measured by ELISA. IL-8 produced by mock-treated cells (26
± 1.1 pg/ml) was taken as 100%. ***p < 0.005 (treatment vs mock). b
AZ11645373 inhibits OxPAPC-stimulated upregulation of IL-8. After
preincubation of HUVECtert with different concentrations of AZ11645373
in the same medium as above for 20 min, OxPAPC (40 μg/ml final concen-
tration) was added. After 7 h, the cell culture supernatants were collected and
the IL-8 concentrations determined by ELISA. IL-8 released after stimulation
of cells with OxPAPC (155 ± 3.2 pg/ml) after subtraction of mock-treated
control (40 ± 1.0 pg/ml) is expressed as 100%. ***p< 0.005 (vs OxPAPC
without inhibitor). The remaining cells were analyzed by theXTTassay (c). A
solution of XTT/PMS was added to cells and incubated for another 2 h at
37 °C followed by absorbance measurement at 450 nm. Cells pretreated with
0.2% Triton X-100 for 15 min before the addition of the XTT/PMS solution
representmetabolically inactive cells. Blank valuesweremeasured in cell-free
wells. The results are expressed as percentage of mock-treated cells (no
OxPAPC, no inhibitor).
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in IL-8 induction, we applied a chemically different P2X7
agonist A740003. As illustrated by Fig. 3d, A740003 did
not inhibit IL-8 release induced by OxPAPC thus
suggesting that the inhibitory action of AZ11645373 on














































































Fig. 2. AZ11645373 inhibits OxPAPC-induced upregulation of IL-8 (a) and COX-2 (b) mRNA in endothelial cells. HUVECtert cells were preincubated
with AZ11645373 in EBM-2 medium containing 2% FCS and 20 mM HEPES at 37 °C. After 20 min, OxPAPC was added and the cells were further
incubated for 7 h. The isolation of total RNA, cDNA synthesis, and real-time PCR were performed as described in the BMaterials and Methods^ section.














































































Fig. 3. P2X7 receptor is not involved in the IL-8 release by ECs. HUVECtert were preincubated with AZ11645373 (final concentration 1 or 3 μM) for
20 min at 37 °C followed by addition of ATP (a) or BzATP (b). After 7 h, the cell culture supernatants were collected and analyzed by the IL-8 ELISA. c
Upregulation of IL-8 by OxPAPC is not dependent on caspase-1. HUVECtert were pretreated with a caspase-1 inhibitor (Ac-YVAD-cmk, final
concentrations are indicated) or AZ11645373 (3 μM) for 20 min, followed by addition of OxPAPC (40 μg/ml). After 7 h, the cell culture medium was
collected and analyzed by IL-8 ELISA. ***p < 0.005 (vs OxPAPC alone). d HUVECtert were preincubated with A740003 (final concentrations are
indicated) for 20 min. After addition of OxPAPC (40 μg/ml), cells were incubated for further 7 h. The collected supernatants were analyzed by IL-8 ELISA.
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We next addressed a question whether AZ11645373
can inhibit action of other pro-inflammatory stimuli like
LPS and TNFα. Both LPS and TNFα stimulated IL-8
secretion, which was inhibited by AZ11645373 (Fig. 4a).
The inhibitory effect did not result from the toxic action of
AZ11645373 because the drug did not impair metabolic
activity of cells determined by a XTT assay at the end of
the experiment (Fig. 4b).
DISCUSSION
A novel finding done in this work is that a P2X7
antagonist AZ11645373 inhibited expression of inflamma-
tory molecules induced by chemically different classes of
agonists including inflammatory cytokines, bacterial PAMPs
(lipopolysaccharide), and endogenously generated DAMPs
(lipid oxidation products such as OxPAPC). In addition to
IL-8, AZ11645373 inhibited induction of COX-2 (PTGS2)
gene and thus has a potential to block multiple facets in
initiation and propagation of inflammation.
The mechanism of the broad anti-inflammatory
action of AZ11645373 is not known. Sathanoori et al.
have recently shown that pharmacological inhibition or
knockdown of P2X7 and P2X4 receptors prevented
upregulation of inflammatory cytokines in cells cul-
tured for 48 h in the presence of high concentrations
of glucose and palmitic acid [13]. The authors provid-
ed mechanistic evidence showing that glucose/palmitic
acid treatment increased concentrations of extracellular
ATP thus leading to the activation of P2X7-dependent
pro-inflammatory pathways. Our data however point to
the existence of an alternative mechanism of anti-
inflammatory action of AZ11645373, which is P2X7
receptor-independent. Indeed, under our experimental
conditions P2X7 receptor agonists ATP or BzATP did
not induce IL-8. Furthermore, another chemically dif-
ferent P2X7 antagonist (A740003) did not inhibit ele-
vation of IL-8 induced by OxPAPC. The data suggest
that AZ11645373 inhibits inflammation independently
of P2X7 receptor, i.e., through an off-target mecha-
nism. The inhibition was observed at submicromolar
concentrations of AZ11645373, which makes non-
specific physicochemical mechanisms unlikely. One
plausible explanation is that AZ11645373 binds to an
alternative intracellular target different from P2X7 re-
ceptor and thus inhibits pro-inflammatory signaling
pathways. The major pro-inflammatory transcription fac-
tor NF-κB is unlikely to be the (only) target of
AZ11645373. Although the NF-κB-driven transcription
plays a central role in the induction of IL-8 by TNFα and
LPS [14] OxPAPC does not activate NF-κB [11, 15] and
induces IL-8 through multiple signaling and transcriptional
mechanisms including c-Src, STAT3, and ATF4 [16–22].
At the moment, there are no indications that any of these
proteins can be inhibited by AZ11645373. Therefore,
LPS, 30 ng/ml -
-
0.3 10.10.03
TNF , 0.3 ng/ml
+ + + + +
+ + + + +
- - - - -


















































































































Fig. 4. AZ11645373 prevents LPS- and TNFα-induced IL-8 release in
endothelial cells. HUVECtert were pretreated with AZ11645373 at different
concentrations for 20 min followed by addition of LPS (30 ng/ml) or TNFα
(0.3 ng/ml). After 7 h, the cell culture supernatants were collected and
analyzed by IL-8 ELISA (a). IL-8 release in the absence of inhibitor was
177 ± 46.4 pg/ml (LPS), 910 ± 45.2 pg/ml (TNFα) and 49 ± 4.4 pg/ml
(mock-treatment). The respective IL-8 release by LPS or TNFα was set as
100%. *p < 0.05, ***p < 0.005 (vs LPS/TNFα treatment alone) (b). The cells
remaining after themedium collectionwere treatedwith a XTT/PMS solution
for analysis of metabolic activity as described in the legend to Fig. 1c.
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further pharmacological and target fishing studies are re-
quired in order to identify protein targets of AZ11645373
mediating its P2X7-independent anti-inflammatory action.
In summary, our data suggest that AZ11645373 in
addition to its well-characterized ability to inhibit pro-
inflammatory action of ATP demonstrates a broad P2X7
receptor-independent anti-inflammatory activity against
chemically different types of inflammatory agonists. This
type of polypharmacology may be especially effective for
treatment of inflammatory disorders due to a combination
of P2X7-dependent and P2X7-independent anti-inflamma-
tory mechanisms. In other words, AZ11645373 has a po-
tential to induce several beneficial effects including inhibi-
tion of inflammasome-mediated generation of IL-1β and
IL-18, inhibition of inflammatory pain, as well as broad
anti-inflammatory action described in this work.
BSA, bovine serum albumin; DAMP, danger-
associated molecular pattern; EBM, endothelial basal me-
dium; FCS, fetal calf serum; HUVEC, human umbilical
vein endothelial cell; IL-8, interleukin-8; LPS, lipopoly-
saccharide; OxPL, oxidized phospholipid; PAMP,
pathogen-associated molecular pattern; PAPC, 1-
palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine;
TNF, tumor necrosis factor.
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